BMIQ1
MCID: BDY007
MIFTS: 38

Body Mass Index Quantitative Trait Locus 1 (BMIQ1)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 57
Body Mass Index 57 16
Bmi 57 47
Bmiq1 57

Classifications:



External Ids:

OMIM® 57 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM®: 57 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). For discussion of genetic heterogeneity of BMI quantitative trait loci and their known or possible associations with variation in specific genes, see MAPPING and MOLECULAR GENETICS sections. (606641) (Updated 08-Dec-2022)

MalaCards based summary: Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 9 and body mass index quantitative trait locus 10. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Leuprolide and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and prostate.

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1555)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 9 11.8
2 body mass index quantitative trait locus 10 11.8
3 body mass index quantitative trait locus 11 11.8
4 body mass index quantitative trait locus 4 11.8
5 body mass index quantitative trait locus 18 11.8
6 body mass index quantitative trait locus 14 11.7
7 body mass index quantitative trait locus 12 11.7
8 body mass index quantitative trait locus 19 11.7
9 body mass index quantitative trait locus 20 11.7
10 body mass index quantitative trait locus 7 11.6
11 chromosome 16p11.2 deletion syndrome, 220-kb 11.6
12 body mass index quantitative trait locus 8 11.6
13 body mass index quantitative trait locus 3 11.5
14 body mass index quantitative trait locus 5 11.5
15 body mass index quantitative trait locus 6 11.5
16 body mass index quantitative trait locus 15 11.5
17 siddiqi syndrome 11.4
18 obesity-hypoventilation syndrome 11.4
19 body mass index quantitative trait locus 2 11.3
20 body mass index quantitative trait locus 13 11.3
21 esophageal cancer 11.3
22 x-linked intellectual disability-short stature-overweight syndrome 11.3
23 leptin deficiency or dysfunction 11.2
24 intellectual developmental disorder, x-linked 12 11.2
25 hypercholesterolemia, familial, 3 11.2
26 chromosome 16p11.2 duplication syndrome 11.2
27 chromosome 5q12 deletion syndrome 11.2
28 9q31.1q31.3 microdeletion syndrome 11.2
29 genetic non-syndromic obesity 11.2
30 type 2 diabetes mellitus 11.1
31 nutritional deficiency disease 11.1
32 gestational diabetes 11.1
33 diabetes mellitus 11.1
34 oculodentodigital dysplasia 11.0
35 abdominal obesity-metabolic syndrome 1 11.0
36 lipid metabolism disorder 11.0
37 pre-eclampsia 11.0
38 polycystic ovary syndrome 11.0
39 non-alcoholic fatty liver disease 11.0
40 polycystic ovary syndrome 1 11.0
41 heart disease 11.0
42 cardiovascular system disease 10.9
43 coronary heart disease 1 10.9
44 eating disorder 10.9
45 oto-palatal-digital syndrome 10.9
46 morbid obesity and spermatogenic failure 10.9
47 hypertension, essential 10.9
48 leptin receptor deficiency 10.9
49 adult syndrome 10.9
50 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 10.9

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM®:

606641 (Updated 08-Dec-2022)

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
4
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
5
Levonorgestrel Approved, Investigational Phase 4 797-63-7 13109
6
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
9
Sultamicillin Approved, Investigational Phase 4 76497-13-7 2175
10
Sulbactam Approved Phase 4 68373-14-8 5316
11
Insulin detemir Approved Phase 4 169148-63-4 16137271
12 Anesthetics, Local Phase 4
13 Antineoplastic Agents, Hormonal Phase 4
14 Androgens Phase 4
15 Omega 3 Fatty Acid Phase 4
16 Gastrointestinal Agents Phase 4
17 Hypoglycemic Agents Phase 4
18 Contraceptives, Postcoital Phase 4
19
Ulipristal acetate Phase 4 126784-99-4 13559282 130904
20 Contraceptives, Oral Phase 4
21 Contraceptive Agents Phase 4
22 Liver Extracts Phase 4
23 Pancreatin Phase 4
24 Raltegravir Potassium Phase 4
25 Integrase Inhibitors Phase 4
26 Antiviral Agents Phase 4
27 Anti-Retroviral Agents Phase 4
28 Anti-Infective Agents Phase 4
29 Anti-HIV Agents Phase 4
30 HIV Protease Inhibitors Phase 4
31 HIV Integrase Inhibitors Phase 4
32 Reverse Transcriptase Inhibitors Phase 4
33
protease inhibitors Phase 4
34 Anti-Bacterial Agents Phase 4
35 Antibiotics, Antitubercular Phase 4
36 Insulin, Globin Zinc Phase 4
37
Insulin Phase 4
38 beta-Lactamase Inhibitors Phase 4
39
Zinc cation Approved, Experimental, Investigational Phase 2, Phase 3 7440-66-6, 23713-49-7 32051
40
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
41 Dermatologic Agents Phase 2, Phase 3
42
Licogliflozin Investigational Phase 2 1291094-73-9 52913524
43
Indole-3-carbinol Investigational Phase 2 700-06-1 3712
44
Indole Experimental Phase 2 120-72-9 798
45 Sodium-Glucose Transporter 2 Inhibitors Phase 2
46 Estrogens Phase 2
47 Protective Agents Phase 2
48
Pravastatin Approved Phase 1 81093-37-0 54687
49
Glucagon Approved Phase 1 16941-32-5 16133228 16186314
50
Resveratrol Investigational Phase 1 501-36-0 445154

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
2 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
3 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
4 The Effect of Body Mass Index, Intra-abdominal Pressure, Abdominal Girth and Waist Circumference on Sensory Block Level After Single-shot Spinal Anesthesia for Cesarean Section Unknown status NCT03164096 Phase 4 Bupivacaine Hydrochloride
5 Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial. Completed NCT01876875 Phase 4
6 Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index Completed NCT02689804 Phase 4 LNG-EC;UPA-EC
7 Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
8 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
9 Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25. Completed NCT00356148 Phase 4 Ampicillin/Sulbactam
10 A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET) Completed NCT01232491 Phase 4 Insulin detemir
11 High Protein Diet , Adiponectin and Inflammatory Factors Completed NCT01886495 Phase 3
12 Effect of High Protein Diet on Cardiovascular Diseases Risk Factors Among Overweight and Obese Children Completed NCT01886482 Phase 3
13 High Protein Diet , CRP and CVD Risk Factors Completed NCT01763528 Phase 3
14 Effects of Zinc Supplementation on Weight, Body Mass Index (BMI), Waist Circumference, Fat Mass and Lean Mass, Apelin and Inflammatory Markers in Obese Individuals Completed NCT02516475 Phase 2, Phase 3
15 Effect of Mindful Eating on Body Mass Index and Cardiovascular Risk Markers in Obese Adolescents: A Pilot Randomized Clinical Trial Completed NCT01764113 Phase 3
16 An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 30 kg.m2 and Hyperinsulinemia Active, not recruiting NCT01697566 Phase 3 Metformin
17 A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index Completed NCT02470403 Phase 2 LIK066;Placebo
18 A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2) Completed NCT04874233 Phase 2 HU6;Placebo
19 A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index Completed NCT01312467 Phase 2 metformin hydrochloride
20 Intermittent Fasting for Patients With HER2- Negative and ER/PR <10% Breast Cancer and Body Mass Index >= 25 Receiving Neoadjuvant Chemotherapy Recruiting NCT05327608 Phase 2
21 Effects of Dietary Indole-3-Carbinol on Estrogen Metabolites Across a Wide Range of Body Mass Index: Implications for the Prevention of Endometrial Cancer in Obese Women Terminated NCT00988845 Phase 2
22 Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541 Completed NCT01818245 Phase 1 LY2605541
23 Pilot Study of Resveratrol in Postmenopausal Women With High Body Mass Index Completed NCT01370889 Phase 1 resveratrol
24 Pilot Trial of Pravastatin as a Novel Prophylactic Medicine to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index Recruiting NCT05524246 Phase 1 Pravastatin
25 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index Recruiting NCT05203237 Phase 1
26 A Phase 1, First-in-Human, Double-blind, Placebo-controlled, Single-and Multiple-Ascending Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease Enrolling by invitation NCT05517564 Phase 1 GM-60106
27 A Comparative Effectiveness Research Study Comparing Changes in Body Composition and Parent Ratings of Quality of Life in 5-19 Year Olds as a Function of Participation in One of Four Versions of the Good NEWS 4 Kids Program (GN4K) Unknown status NCT01855009
28 The Genetic Basis of the Influence of Dairy Product Intake on Body Measures in Children Unknown status NCT01831557
29 Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome (Randamized Control Trial) Unknown status NCT03291405
30 Assessment of the Effect of Obesity on Venous Puncture Pain Unknown status NCT03689205
31 Age and Gender Corrected Body Mass Index: When Preoperative Weight Loss and Underweight Are Becomming Clinically Significant in Esophagectomy for Cancer. Unknown status NCT01958697
32 Efficacy of Oral Vitamin D Supplementation in Reducing Body Mass Index and Lipid Profile in Adolescents and Young Adults in Colombia: a Pilot Clinical Trial Protocol Nested in the SIMBA Cohort Unknown status NCT04377386
33 Effect of Modified Laparoscopic Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetics With Lower Body Mass Index in China Unknown status NCT02091323
34 The Relationship Between Transvaginal Ultrasound Endometrial Thickness and Body Mass Index and Pathology in Postmenopausal Bleeding Unknown status NCT03841916
35 Effect of Synbiotic Supplement on the Body Mass Index of Participants With Severe Obesity Unknown status NCT02958644
36 The Difference Seen in Granulosa Cells and Immature Oocytes in IVF Treated Patients Sorted by Body Mass Index (BMI) Unknown status NCT03020173
37 A Pragmatic, Randomised, Controlled, Trial of the Effect of the Counterweight Plus Weight Management Programme in Uncontrolled Asthma Associated With Elevated Body Mass Index Unknown status NCT03858608
38 A Mixed Retrospective-prospective, Observational Study Evaluating the Efficacy of Counselling in a Remote Setting Compared to an In-person Setting on Weight Loss, in Obese Patients With Body Mass Index > 35 Kg/m2 and Enrolled in the Behaviour Modification Program at the Bariatric Centre of Excellence at St Joseph's Healthcare Hamilton. Unknown status NCT04658550
39 Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients Unknown status NCT03873064
40 The Association Between Periodontal Health Status, Body Mass Index and Quality of Diet in a Sample of Adult Egyptian Patients. A Hospital Based Cross-sectional Study Unknown status NCT04557670
41 Prospective, Observational Study of Evaluation of Body Mass Index and Eating Behaviour Changes in Female Patients With Fibromyalgia Under Medical Treatment Unknown status NCT03394898
42 Effect of Increased Body Mass Index on Auditory Function Unknown status NCT03172663
43 Obesity Index That Better Predict Ovarian Response: Body Mass Index, Waist Circumference, Waist Hip Ratio, or Waist Height Ratio in Women Undergoing ICSI Unknown status NCT02520765
44 Developmental Pathways to Metabolic Diseases: Metabolic Physiology, Epigenetics and Body Composition in Healthy Overweight and Obese Subjects With a Fixed Range of Body Mass Index in Singapore - To Investigate the Influence of Ethnicity Unknown status NCT00988819
45 Impact of Body Mass Index on Outcomes of Breast Cancer Management (Retrospective Study) Unknown status NCT03429504
46 The Relationship Between Genetics, Body Mass Index, Fat Intake, Fat Taste Sensitivity and Food Preference Unknown status NCT03666182
47 A Pragmatic, Randomised, Controlled, Trial of the Effect of a Tailored Pulmonary Rehabilitation Package in Uncontrolled Asthma Associated With Elevated Body Mass Index Unknown status NCT03630432
48 The Effect of Diet Counseling for Low Calorie-High Protein on the Body Composition (Weight, Body Mass Index, Fat Mass (kg), Fat Mass Percentage, Muscle Mass (kg), Muscle Mass Percentage, Inflammation Marker (High-sensitivity C-reactive Protein), and Oxidative Stress Marker (Malondialdehyde and Glutathione) in Obese People With Weight Cycling in Jakarta Unknown status NCT03374150
49 Cognitive Function and Body Mass Index in Children and Adolescents Unknown status NCT03963557
50 Can a Higher Body Mass Index and a Positive Stop Bang or Epworth Sleepiness Scale Questionnaire Predict Cardiorespiratory Adverse Events During Endoscopy: A Prospective Cohort Study Unknown status NCT03436381

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

Organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

MalaCards : Breast, Liver, Prostate, Heart, Ovary, Bone, Skeletal Muscle

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 30008)
# Title Authors PMID Year
1
Genetic studies of body mass index yield new insights for obesity biology. 62 57
25673413 2015
2
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. 62 57
20935630 2010
3
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. 62 57
14569127 2003
4
A study of linkage and association of body mass index in the Old Order Amish. 62 57
12888987 2003
5
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. 62 57
12355400 2002
6
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. 62 57
11713718 2002
7
Familial aggregation of body mass index and subcutaneous fat measures in the longitudinal Québec family study. 62 57
10096693 1999
8
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. 62 57
9806549 1998
9
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. 62 57
9758619 1998
10
New genetic loci link adipose and insulin biology to body fat distribution. 57
25673412 2015
11
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. 57
21706003 2011
12
The genetic contribution to non-syndromic human obesity. 57
19506576 2009
13
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 57
19151714 2009
14
Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. 57
17855449 2007
15
Genetic pleiotropy between asthma and obesity in a community-based sample of twins. 57
16337451 2005
16
Genome-wide scan of obesity in the Old Order Amish. 57
11238509 2001
17
Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. 57
10523018 1999
18
Physical activity and body mass index were interactively related to health-related quality of life among older adults. 62
36240587 2023
19
Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis. 62
36316116 2023
20
Considerations When Using Body Mass Index as a Size Descriptor. 62
35590463 2023
21
Obstacle clearance performance in individuals with high body mass index. 62
36058167 2023
22
Cross-sectional associations between exposure to per- and polyfluoroalkyl substances and body mass index among European teenagers in the HBM4EU aligned studies. 62
36334774 2023
23
The relationship between body mass index and food preoccupation in women: A moderated mediation of body-related self-conscious emotions and self-esteem. 62
36352323 2023
24
Triponderal mass index is as strong as body mass index in the determination of obesity and adiposity. 62
36265325 2023
25
Association between body mass index change and mortality in critically ill patients: A retrospective observational study. 62
36413821 2023
26
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol. 62
36006839 2022
27
Differential impact of low fat-free mass in people with COPD based on body mass index classifications: results from COSYCONET. 62
36470414 2022
28
Association of high body mass index, waist circumference, and body fat percentage with sarcopenia in older women. 62
36471279 2022
29
Association of body mass index with COVID-19 related in-hospital death. 62
35397941 2022
30
Association of body mass index and intestinal (faecal) Streptococcus in adults in Xining city, China P.R. 62
36264094 2022
31
Risks and benefits of oral anticoagulants for stroke prophylaxis in atrial fibrillation according to body mass index: Nationwide cohort study of primary care records in England. 62
36353266 2022
32
Insulin and body mass index decrease serum soluble leptin receptor levels in humans. 62
36459457 2022
33
Does Body Mass Index Influence Long-Term Outcomes After Anatomic Total Shoulder Arthroplasty? 62
36464204 2022
34
Comparing body mass index and obesity-related comorbidities as predictors in hospitalized COVID-19 patients. 62
36354347 2022
35
Body Mass Index as a Proxy Indicator for Poor Oral Hygiene Habits in Adult Diabetic Patients. 62
36348968 2022
36
Does Central Fat Distribution Reduction After Bariatric Surgery Induce Ocular Refraction Change Independent of Body Mass Index? 62
36269522 2022
37
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes. 62
36461034 2022
38
Gene expression associations with body mass index in the Multi-Ethnic Study of Atherosclerosis. 62
36463326 2022
39
Association between distinct body mass index trajectories according to the group-based trajectory modeling and the risk of incident diabetes: A systematic review. 62
36269000 2022
40
Obesity Classification of the Body Mass Index Does Not Predict Participation Restrictions at Work. 62
36136664 2022
41
Association between body mass index and difficult intubation with a double lumen tube: A retrospective cohort study. 62
36219977 2022
42
Global burden of asthma associated with high body mass index from 1990 to 2019. 62
36002091 2022
43
Put your weight behind it-Effect of body mass index on the active second stage of labour: A retrospective cohort study. 62
35404537 2022
44
Relation between perinatal outcome and gestational duration in term primiparous pregnancies stratified by body mass index. 62
36168197 2022
45
Associations of body mass index, fasting insulin, and inflammation with mortality: a prospective cohort study. 62
36030344 2022
46
Body mass index and complications after obstetric anal sphincter injury, 8 weeks postpartum. 62
36085318 2022
47
Comment on "Association-19 of body mass index with COVID-19 related in-hospital death" Clinical Nutrition 2022. 62
35577618 2022
48
Correlation between body mass index and COVID-19 transmission risk. 62
36002512 2022
49
The relationship between body mass index and stroke: a systemic review and meta-analysis. 62
35971008 2022
50
The relation between body mass index and primary dysmenorrhea: A systematic review and meta-analysis. 62
36124820 2022

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....